Developer docs
API playgroundTry for free, no card

Search company profiles

Treeway

Full company profile

uuid000can4

Namestring
Treeway
Legal namestring
Treeway B.V.
Websiteurl
treeway.nl
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Treeway B.V. is a privately held, clinical-stage biotechnology company founded in 2012 in Tilburg, the Netherlands, by two ALS patients, Bernard Muller and Robbert Jan Stuit, with the mission of developing disease-modifying therapies for ALS, Alzheimer's disease, and other neurodegenerative conditions. The company's lead asset, TW001 (also known as FNP122), is a patented oral formulation of the free-radical scavenger edaravone designed to improve bioavailability and patient convenience over the intravenous reference product Radicava. The pipeline also includes TW002, a combination therapy for Alzheimer's disease, and preclinical programs targeting new ALS pathways, supported by biomarker and genetics research collaborations with academic centers including ALS Centrum Nederland, Alzheimer Center Amsterdam, and TRICALS. Treeway holds Orphan Drug Designations for TW001 from both the EMA (2014) and the FDA (2015).

Operationally, Treeway runs a minimalist organization of 1-10 employees and a lean management team led by CEO Inez de Greef, supported by a Scientific Advisory Board that includes Prof. Philip Scheltens and Prof. Leonard van den Berg. The company does not commercialize products directly; instead, it pursues an asset-out licensing model. TW001/FNP122 was licensed to Ferrer for ALS development and commercialization in Europe and select Asian markets in October 2021, and to Specialised Therapeutics Asia for Australia and New Zealand in August 2023. R&D is co-funded by non-dilutive grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer Drug Discovery Foundation. The Phase 3 ADORE trial for ALS failed to meet its primary endpoints in January 2024, but the Phase 2a ASURE trial in mild-to-moderate Alzheimer's disease completed enrollment in September 2024, with results accepted for late-breaking presentation at the CTAD 2025 conference.

Short descriptiontext

Treeway is a Netherlands-based clinical-stage biotechnology company developing oral edaravone (TW001) and other therapies for ALS and Alzheimer's disease, monetizing through regional licensing partnerships and non-dilutive grants rather than direct commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTilburg, Netherlands
HQ citystring
Tilburg
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapies, ALS drug development, Alzheimer's disease treatment, clinical-stage biotechnology, oral edaravone formulation
Industry1 code
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

Treeway licenses its drug candidates to pharmaceutical partners for development and commercialization. Under the Ferrer agreement, Ferrer is responsible for advancing development and commercialization and makes royalty payments to Treeway at certain milestones. Similar arrangement with Specialised Therapeutics for Australia/New Zealand.

treeway.nl
2Grant Funding
TypeLicensing Royalties
Description

Treeway's development programs are co-funded by external organizations including the Alzheimer Drug Discovery Foundation (ADDF), the United States Department of Defense (DoD), and The Dutch Ministry of Economic Affairs' Innovation Credit.

treeway.nl
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1TW001
Description

Oral edaravone formulation - Treeway's lead product targeting oxidative stress for ALS and Alzheimer's disease treatment.

treeway.nl
+3 more records
Core offering1 text field

Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, with lead candidate TW001 (an oral formulation of edaravone) being progressed in a Phase 2a ASURE trial for Alzheimer's disease following a completed Phase 3 ADORE study in ALS, and a second candidate TW002 in earlier-stage development. The company advances candidates through clinical development and out-licenses regional commercialization rights to pharmaceutical partners such as Ferrer (Europe, parts of Asia) and Specialised Therapeutics (Australia, New Zealand) in exchange for milestone payments and royalties. Development is co-funded by grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer's Drug Discovery Foundation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Oral formulation bioavailability exceeded that of intravenous Radicava infusion in Phase 1 study
+2 more records
Product overview1 text field

Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, particularly ALS and Alzheimer's disease. The company's pipeline consists of two main drug products: TW001 (lead product, oral edaravone formulation) and TW002. TW001 is being developed for both ALS and Alzheimer's disease, having received Orphan Drug Designation from both EMA (2014) and FDA (2015). Discovery programs include biomarkers and genetics, motor neuron signaling, and immune system research.

Product and service2 records
1TW001 (Oral Edaravone)
CategoryInvestigational drug therapy (oral small molecule)
Description

TW001 is Treeway's lead investigational product: a patented, patient-friendly oral formulation of the free radical scavenger edaravone, developed as a disease-modifying therapy targeting oxidative stress in ALS and Alzheimer's disease. It is designed for daily oral dosing to replace or complement existing intravenous edaravone (Radicava) therapy, with improved bioavailability demonstrated in Phase 1 and clinical evaluation ongoing in the Phase 2a ASURE study for Alzheimer's disease (and previously in the Phase 3 ADORE study for ALS). The product is out-licensed to Ferrer (as FNP122) for Europe and selected Asian countries and to Specialised Therapeutics for Australia and New Zealand.

2TW002
CategoryInvestigational drug therapy (pipeline)
Description

TW002 is the second drug candidate in Treeway's pipeline for neurodegenerative diseases, currently in preclinical/early development. It is referenced alongside TW001 as part of Treeway's broader effort to develop disease-modifying therapies for ALS and other neurodegenerative indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-28
Description

Licensing partnership to commercialise TW001 for ALS/MND in Australia and New Zealand. ST is an international biopharmaceutical company headquartered in Singapore, responsible for all marketing, regulatory and distribution activities in the region. This is ST's first CNS therapy in their portfolio.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-10-20
Description

Licensing agreement for development and commercialisation of oral edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis in certain territories including Europe and some Asian countries. Ferrer is responsible for advancing development and commercialisation and will make royalty payments to Treeway at certain milestones. Ferrer is an international pharmaceutical company focused on neurological disorders and pulmonary vascular diseases.

33D-PharmXchange
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Drug development partner and pharmaceutical consultancy company founded by Treeway co-founders Inez de Greef and Ronald van der Geest. Provides fit-for-purpose drug development solutions to clients in pharma, biotech and healthcare companies with long-standing experience in managing multi-disciplinary projects.

treeway.nl
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The ALS Center in The Netherlands is led by director Dr. Leonard H. van den Berg and provides diagnosis, care and treatment for ALS patients. Part of the University Medical Center (UMC) in Utrecht. Treeway collaborates for biomarker and genetic research.

5Alzheimer center Amsterdam
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Part of Amsterdam UMC specializing in Alzheimer and dementia research. Over 100 employees provide diagnosis and treatment. Director Philip Scheltens is one of the top ten most cited scientists in Alzheimer research. Treeway collaborates to evaluate potential treatments and research the neurodegenerative disease.

treeway.nl
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Treatment Research Institute for the Cure of ALS is an international online platform for people with ALS. Treeway actively collaborates with TRICALS to accelerate clinical research to ultimately find effective treatment for ALS. Supported the ADORE Phase III clinical trial.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Largest ALS research consortium devoted to discovering the genetic make-up for ALS. Initiated by Treeway founders Bernard Muller and Robbert Jan Stuit. Goal is to identify genes associated with ALS whose function may lead to disease pathways.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cytokinetics is a clinical-stage biopharmaceutical company focused on developing muscle activators for ALS and other neuromuscular diseases. It is a direct peer given Treeway's overlapping ALS focus and shared reliance on ALS patient community engagement and Phase 3 clinical execution.

TypeDirect peer
Description

Anavex is a clinical-stage biotechnology company developing small-molecule therapeutics for Alzheimer's disease, Rett syndrome, and other neurodegenerative indications. It is comparable to Treeway given the shared focus on orally bioavailable small molecules targeting CNS/neurodegenerative diseases at similar clinical-stage maturity.

TypeDirect peer
Description

Prothena is a clinical-stage biotech developing protein-immunomodulatory therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. It is a direct peer to Treeway given overlapping neurodegenerative pipeline focus, clinical-stage development, and reliance on similar academic and big-pharma partnership models.

4AB Science
TypeDirect peer
Description

AB Science is a clinical-stage pharmaceutical company developing tyrosine kinase inhibitors, including masitinib for ALS. It is a direct peer to Treeway given the shared ALS indication focus, small-molecule approach, and similar clinical-stage development of disease-modifying therapies for a rare neurodegenerative indication.

TypeDirect peer
Description

Ionis is a clinical- and commercial-stage antisense oligonucleotide developer with programs in ALS (e.g., tofersen collaboration with Biogen) and other neurological disorders. It is a direct peer given the shared ALS development focus, comparable clinical-stage programs, and CNS drug-development orientation.

TypeEmerging player
Description

Denali Therapeutics is a clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, ALS, and Alzheimer's, using a targeted degradation and blood-brain barrier delivery platform. It is an emerging player comparable to Treeway given shared neurodegenerative focus and clinical-stage maturity, though Denali operates with broader indications and a larger platform.

TypeBroad incumbent
Description

Biogen is a major global biopharmaceutical company with a broad neurodegenerative disease franchise including Qalsody for ALS and Aduhelm/lecanemab in Alzheimer's. It is a broad incumbent peer given its established leadership in the same neurodegenerative indications where Treeway operates and its role as a potential licensing/acquisition counterparty.

8Eisai
TypeBroad incumbent
Description

Eisai is a major global pharmaceutical company with a leading Alzheimer's franchise (lecanemab, in partnership with Biogen) and CNS development capabilities. It is a broad incumbent peer given its established position in the Alzheimer's market where Treeway's TW001 oral edaravone would compete.

TypeEmerging player
Description

AZTherapies is a clinical-stage biotechnology company developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's. It is an emerging player comparable to Treeway given the similar focus on orally administered disease-modifying small molecules for neurodegenerative indications.

TypeRegional player
Description

reMYND is a Belgium-based clinical-stage biotech developing therapeutics targeting neurodegenerative diseases, particularly Alzheimer's and Parkinson's. It is a regional player comparable to Treeway given shared European base, similar clinical-stage maturity, and overlapping neurodegenerative disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Treeway

Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics)treeway.nl

Treeway is a Netherlands-based clinical-stage biotechnology company developing oral edaravone (TW001) and other therapies for ALS and Alzheimer's disease, monetizing through regional licensing partnerships and non-dilutive grants rather than direct commercialization.

What Treeway does

Treeway B.V. is a privately held, clinical-stage biotechnology company founded in 2012 in Tilburg, the Netherlands, by two ALS patients, Bernard Muller and Robbert Jan Stuit, with the mission of developing disease-modifying therapies for ALS, Alzheimer's disease, and other neurodegenerative conditions. The company's lead asset, TW001 (also known as FNP122), is a patented oral formulation of the free-radical scavenger edaravone designed to improve bioavailability and patient convenience over the intravenous reference product Radicava. The pipeline also includes TW002, a combination therapy for Alzheimer's disease, and preclinical programs targeting new ALS pathways, supported by biomarker and genetics research collaborations with academic centers including ALS Centrum Nederland, Alzheimer Center Amsterdam, and TRICALS. Treeway holds Orphan Drug Designations for TW001 from both the EMA (2014) and the FDA (2015).

Operationally, Treeway runs a minimalist organization of 1-10 employees and a lean management team led by CEO Inez de Greef, supported by a Scientific Advisory Board that includes Prof. Philip Scheltens and Prof. Leonard van den Berg. The company does not commercialize products directly; instead, it pursues an asset-out licensing model. TW001/FNP122 was licensed to Ferrer for ALS development and commercialization in Europe and select Asian markets in October 2021, and to Specialised Therapeutics Asia for Australia and New Zealand in August 2023. R&D is co-funded by non-dilutive grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer Drug Discovery Foundation. The Phase 3 ADORE trial for ALS failed to meet its primary endpoints in January 2024, but the Phase 2a ASURE trial in mild-to-moderate Alzheimer's disease completed enrollment in September 2024, with results accepted for late-breaking presentation at the CTAD 2025 conference.

Treeway firmographics

Firmographics
Name
Treeway
Legal name
Treeway B.V.
Website
https://treeway.nl
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Treeway is a Netherlands-based clinical-stage biotechnology company developing oral edaravone (TW001) and other therapies for ALS and Alzheimer's disease, monetizing through regional licensing partnerships and non-dilutive grants rather than direct commercialization.
Ownership category
akta.pro rank

Treeway industry classification

Industry
Product category
Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Neurodegenerative disease therapies
  • ALS drug development
  • Alzheimer's disease treatment
  • Clinical-stage biotechnology
  • Oral edaravone formulation

Where Treeway is headquartered

Location

Headquarters

HQ city
Tilburg
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Treeway business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Royalties: Treeway licenses its drug candidates to pharmaceutical partners for development and commercialization. Under the Ferrer agreement, Ferrer is responsible for advancing development and commercialization and makes royalty payments to Treeway at certain milestones. Similar arrangement with Specialised Therapeutics for Australia/New Zealand.
  2. Grant Funding: Treeway's development programs are co-funded by external organizations including the Alzheimer Drug Discovery Foundation (ADDF), the United States Department of Defense (DoD), and The Dutch Ministry of Economic Affairs' Innovation Credit.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Treeway product offering

Product offering

Core offering

Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, with lead candidate TW001 (an oral formulation of edaravone) being progressed in a Phase 2a ASURE trial for Alzheimer's disease following a completed Phase 3 ADORE study in ALS, and a second candidate TW002 in earlier-stage development. The company advances candidates through clinical development and out-licenses regional commercialization rights to pharmaceutical partners such as Ferrer (Europe, parts of Asia) and Specialised Therapeutics (Australia, New Zealand) in exchange for milestone payments and royalties. Development is co-funded by grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer's Drug Discovery Foundation.

Product overview

Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, particularly ALS and Alzheimer's disease. The company's pipeline consists of two main drug products: TW001 (lead product, oral edaravone formulation) and TW002. TW001 is being developed for both ALS and Alzheimer's disease, having received Orphan Drug Designation from both EMA (2014) and FDA (2015). Discovery programs include biomarkers and genetics, motor neuron signaling, and immune system research.

Differentiator

Problem solved

Functional benefit

Brands

  • TW001: Oral edaravone formulation - Treeway's lead product targeting oxidative stress for ALS and Alzheimer's disease treatment.
  • FNP122
  • ASURE
  • ADORE

Products and services

  • TW001 (Oral Edaravone) TW001 is Treeway's lead investigational product: a patented, patient-friendly oral formulation of the free radical scavenger edaravone, developed as a disease-modifying therapy targeting oxidative stress in ALS and Alzheimer's disease. It is designed for daily oral dosing to replace or complement existing intravenous edaravone (Radicava) therapy, with improved bioavailability demonstrated in Phase 1 and clinical evaluation ongoing in the Phase 2a ASURE study for Alzheimer's disease (and previously in the Phase 3 ADORE study for ALS). The product is out-licensed to Ferrer (as FNP122) for Europe and selected Asian countries and to Specialised Therapeutics for Australia and New Zealand.
  • TW002 TW002 is the second drug candidate in Treeway's pipeline for neurodegenerative diseases, currently in preclinical/early development. It is referenced alongside TW001 as part of Treeway's broader effort to develop disease-modifying therapies for ALS and other neurodegenerative indications.

Quantifiable outcome

  • Oral formulation bioavailability exceeded that of intravenous Radicava infusion in Phase 1 study
  • +2 more outcomes

Companies that use Treeway

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Treeway technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Treeway partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Specialised Therapeutics AsiacoreChannel Partner/ Reseller/ Distributor · 28 August 2023Licensing partnership to commercialise TW001 for ALS/MND in Australia and New Zealand. ST is an international biopharmaceutical company headquartered in Singapore, responsible for all marketing, regulatory and distribution activities in the region. This is ST's first CNS therapy in their portfolio.
  • FerrercoreOEM/ Whitelabel/ Licensing Partner · 20 October 2021Licensing agreement for development and commercialisation of oral edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis in certain territories including Europe and some Asian countries. Ferrer is responsible for advancing development and commercialisation and will make royalty payments to Treeway at certain milestones. Ferrer is an international pharmaceutical company focused on neurological disorders and pulmonary vascular diseases.
  • 3D-PharmXchangeminorImplementation/ SI/ Consulting PartnerDrug development partner and pharmaceutical consultancy company founded by Treeway co-founders Inez de Greef and Ronald van der Geest. Provides fit-for-purpose drug development solutions to clients in pharma, biotech and healthcare companies with long-standing experience in managing multi-disciplinary projects.
  • ALS Centrum NederlandcoreStrategic or Co-development PartnerThe ALS Center in The Netherlands is led by director Dr. Leonard H. van den Berg and provides diagnosis, care and treatment for ALS patients. Part of the University Medical Center (UMC) in Utrecht. Treeway collaborates for biomarker and genetic research.
  • Alzheimer center AmsterdamcoreStrategic or Co-development PartnerPart of Amsterdam UMC specializing in Alzheimer and dementia research. Over 100 employees provide diagnosis and treatment. Director Philip Scheltens is one of the top ten most cited scientists in Alzheimer research. Treeway collaborates to evaluate potential treatments and research the neurodegenerative disease.
  • TRICALScoreStrategic or Co-development PartnerTreatment Research Institute for the Cure of ALS is an international online platform for people with ALS. Treeway actively collaborates with TRICALS to accelerate clinical research to ultimately find effective treatment for ALS. Supported the ADORE Phase III clinical trial.
  • Project MinEminorStrategic or Co-development PartnerLargest ALS research consortium devoted to discovering the genetic make-up for ALS. Initiated by Treeway founders Bernard Muller and Robbert Jan Stuit. Goal is to identify genes associated with ALS whose function may lead to disease pathways.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Treeway competitors and assessment

Company assessment

Direct peers

  • Cytokinetics: Cytokinetics is a clinical-stage biopharmaceutical company focused on developing muscle activators for ALS and other neuromuscular diseases. It is a direct peer given Treeway's overlapping ALS focus and shared reliance on ALS patient community engagement and Phase 3 clinical execution.
  • Anavex Life Sciences: Anavex is a clinical-stage biotechnology company developing small-molecule therapeutics for Alzheimer's disease, Rett syndrome, and other neurodegenerative indications. It is comparable to Treeway given the shared focus on orally bioavailable small molecules targeting CNS/neurodegenerative diseases at similar clinical-stage maturity.
  • Prothena Corporation: Prothena is a clinical-stage biotech developing protein-immunomodulatory therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. It is a direct peer to Treeway given overlapping neurodegenerative pipeline focus, clinical-stage development, and reliance on similar academic and big-pharma partnership models.
  • AB Science: AB Science is a clinical-stage pharmaceutical company developing tyrosine kinase inhibitors, including masitinib for ALS. It is a direct peer to Treeway given the shared ALS indication focus, small-molecule approach, and similar clinical-stage development of disease-modifying therapies for a rare neurodegenerative indication.
  • Ionis Pharmaceuticals: Ionis is a clinical- and commercial-stage antisense oligonucleotide developer with programs in ALS (e.g., tofersen collaboration with Biogen) and other neurological disorders. It is a direct peer given the shared ALS development focus, comparable clinical-stage programs, and CNS drug-development orientation.

Emerging players

  • Denali Therapeutics: Denali Therapeutics is a clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, ALS, and Alzheimer's, using a targeted degradation and blood-brain barrier delivery platform. It is an emerging player comparable to Treeway given shared neurodegenerative focus and clinical-stage maturity, though Denali operates with broader indications and a larger platform.
  • AZTherapies: AZTherapies is a clinical-stage biotechnology company developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's. It is an emerging player comparable to Treeway given the similar focus on orally administered disease-modifying small molecules for neurodegenerative indications.

Broad incumbents

  • Biogen: Biogen is a major global biopharmaceutical company with a broad neurodegenerative disease franchise including Qalsody for ALS and Aduhelm/lecanemab in Alzheimer's. It is a broad incumbent peer given its established leadership in the same neurodegenerative indications where Treeway operates and its role as a potential licensing/acquisition counterparty.
  • Eisai: Eisai is a major global pharmaceutical company with a leading Alzheimer's franchise (lecanemab, in partnership with Biogen) and CNS development capabilities. It is a broad incumbent peer given its established position in the Alzheimer's market where Treeway's TW001 oral edaravone would compete.

Regional players

  • reMYND: reMYND is a Belgium-based clinical-stage biotech developing therapeutics targeting neurodegenerative diseases, particularly Alzheimer's and Parkinson's. It is a regional player comparable to Treeway given shared European base, similar clinical-stage maturity, and overlapping neurodegenerative disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Treeway social profiles

Digital presence

Treeway compliance and trust

Trust signal

Compliance2 records

Treeway financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Treeway leadership team

Management profile

Number of profiles

Profiles10 records

Treeway funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Treeway M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treeway

What does Treeway do?

Treeway is a clinical-stage biotechnology company developing drug therapies for neurodegenerative diseases, with lead candidate TW001 (an oral formulation of edaravone) being progressed in a Phase 2a ASURE trial for Alzheimer's disease following a completed Phase 3 ADORE study in ALS, and a second candidate TW002 in earlier-stage development. The company advances candidates through clinical development and out-licenses regional commercialization rights to pharmaceutical partners such as Ferrer (Europe, parts of Asia) and Specialised Therapeutics (Australia, New Zealand) in exchange for milestone payments and royalties. Development is co-funded by grants from the US Department of Defense, the Dutch Ministry of Economic Affairs' Innovation Credit, and the Alzheimer's Drug Discovery Foundation.

Is Treeway a public or private company?

Treeway is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Treeway founded?

Treeway was founded in 2012. It employs 11 to 50 people.

Where is Treeway based?

Treeway is headquartered in Tilburg, Netherlands, in the Europe region.

How does Treeway make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are grant Funding.

Who are Treeway's main competitors?

Direct peers on record are Cytokinetics, Anavex Life Sciences, Prothena Corporation, AB Science and Ionis Pharmaceuticals. Emerging players are Denali Therapeutics and AZTherapies. Broad incumbents are Biogen and Eisai. reMYND is listed as a regional player.

Does Treeway have an API?

No public API is recorded for Treeway.

What industry is Treeway in?

Treeway's product category is Clinical-Stage Biotechnology (Neurodegenerative Disease Therapeutics). Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals